Formulation And Evaluation Of Floating Microspheres Of Gliclazide

The objective of this study is to create and design buoyant microspheres containing gliclazide, and subsequently assess their properties. Gliclazide, a derivative of sulfonyl urea, is used to treat type-II diabetes. In order to address the medicine's limited solubility in water and improve its absorption when taken orally, floating microspheres were developed as a controlled drug delivery system. The development of this formulation was achieved by the utilization of the ionotropic gelation process. A total of six formulations, labeled F1-F6, were created using natural polymers in three distinct ratios. The micromeritic properties, percentage swelling, buoyancy, in-vitro release, and entrapment efficiency of the microspheres were evaluated. The flow characteristics of all the formulated microspheres were determined to be satisfactory. The formulation that demonstrated the most effectiveness was identified as F6. It exhibits zero order drug release with a rate of 82.15%. Additionally, it has a percentage yield of 88.4%, a percentage swelling of 92%, a buoyancy percentage of 96%, and an entrapment efficiency of 89%. Formulation F6 was prepared, utilizing natural polymers for the first time to generate floating microspheres of gliclazide.